"Canagliflozin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
| Descriptor ID |
D000068896
|
| MeSH Number(s) |
D02.886.778.075 D03.383.903.075 D09.408.348.113
|
| Concept/Terms |
Canagliflozin- Canagliflozin
- Canagliflozin Hemihydrate
- Hemihydrate, Canagliflozin
Canagliflozin, Anhydrous- Canagliflozin, Anhydrous
- Anhydrous Canagliflozin
- 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene - T777973
|
Below are MeSH descriptors whose meaning is more general than "Canagliflozin".
Below are MeSH descriptors whose meaning is more specific than "Canagliflozin".
This graph shows the total number of publications written about "Canagliflozin" by people in this website by year, and whether "Canagliflozin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Canagliflozin" by people in Profiles.
-
Canagliflozin extends life span in genetically heterogeneous male but not female mice. JCI Insight. 2020 11 05; 5(21).
-
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018 08; 85:32-37.
-
A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition. Postgrad Med. 2011 Jul; 123(4):38-45.